Literature DB >> 22493546

Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis.

Ming Geng1, Yong-Cheng Cao, Ying-Jian Chen, Hui Jiang, Li-Quan Bi, Xiao-Hong Liu.   

Abstract

AIM: To investigate the expression and clinical significance of Wnt member 5a (Wnt5a) and receptor tyrosine kinase-like orphan receptor 2 (Ror2) in hepatocellular carcinoma (HCC).
METHODS: In HCC tissues obtained from 85 patients, the protein expressions of Wnt5a, Ror2, β-catenin, and Ki-67 via immunohistochemical staining using the Envision Plus System. The antibody binding was visualized with 3, 3'-diaminobenzidine tetrahydrochloride (DAB) before brief counterstaining with Mayer's hematoxylin. The degree of immunohistochemical staining was recorded using a semiquantitative and subjective grading system. The mRNA expression of Ror2 was examined by real-time reverse transcription polymerase chain reaction, including nineteen of the 85 HCC and three normal liver tissues. The ratios of Ror2 to the housekeeping gene GAPDH represented the normalized relative levels of Ror2 expression. To determine the prognostic factor, the outcome of the 82 patients was determined by reviewing their medical charts. The overall and disease-free survival rates were estimated using the Kaplan-Meier method and compared with the log-rank test. The prognostic analysis was carried out with univariate and multivariate Cox regressions models.
RESULTS: Compared to nontumorous (hepatitis or cirrhotic) tissues, Ror2 mRNA expression was clearly decreased in HCC. Ror2 and Wnt5a protein expressions in the majority of HCC patients (63% and 77%, respectively) was significantly less in tumor tissues, as compared to adjacent nontumorous tissues, and this reduction was correlated with increasing serum α-fetoprotein and tumor stage. In 68% (58/85) of the HCC cases, the expression of β-catenin in tumor tissues was either downregulated in the cellular membrane, upregulated in the cytoplasm, or both. Survival analysis indicated that Wnt5a and Ror2 protein expressions could be regarded as independent prognostic factors for HCC; HCC patients with decreased Wnt5a or Ror2 protein expression had a poorer prognosis than those with elevated Wnt5a and Ror2 expression (P = 0.016, P = 0.007, respectively).
CONCLUSION: Wnt5a and Ror2 may serve as tumor suppressor genes in the development of HCC, and may serve as clinicopathologic biomarkers for prognosis in HCC patients.

Entities:  

Keywords:  Hepatocellular carcinoma; Prognosis; Receptor tyrosine kinase-like orphan receptor 2; Wnt5a; β-catenin

Mesh:

Substances:

Year:  2012        PMID: 22493546      PMCID: PMC3319959          DOI: 10.3748/wjg.v18.i12.1328

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  Intercellular adhesion, signalling and the cytoskeleton.

Authors:  Colin Jamora; Elaine Fuchs
Journal:  Nat Cell Biol       Date:  2002-04       Impact factor: 28.824

Review 2.  Increasingly complex: new players enter the Wnt signaling network.

Authors:  Petra Pandur; Daniel Maurus; Michael Kühl
Journal:  Bioessays       Date:  2002-10       Impact factor: 4.345

3.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas.

Authors:  Marzieh Jönsson; Janna Dejmek; Pär-Ola Bendahl; Tommy Andersson
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

5.  The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling.

Authors:  Tohru Ishitani; Satoshi Kishida; Junko Hyodo-Miura; Naoto Ueno; Jun Yasuda; Marian Waterman; Hiroshi Shibuya; Randall T Moon; Jun Ninomiya-Tsuji; Kunihiro Matsumoto
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 6.  The Ror receptor tyrosine kinase family.

Authors:  W C Forrester
Journal:  Cell Mol Life Sci       Date:  2002-01       Impact factor: 9.261

7.  Expression of transforming growth factor-beta 1 in hepatocellular carcinoma in comparison with the non-tumor tissue.

Authors:  Youko Idobe; Yoshikazu Murawaki; Yukisato Kitamura; Hironaka Kawasaki
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

8.  Wnt-5a has tumor suppressor activity in thyroid carcinoma.

Authors:  N Kremenevskaja; R von Wasielewski; A S Rao; C Schöfl; T Andersson; G Brabant
Journal:  Oncogene       Date:  2005-03-24       Impact factor: 9.867

9.  Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis.

Authors:  T Yamada; A S Takaoka; Y Naishiro; R Hayashi; K Maruyama; C Maesawa; A Ochiai; S Hirohashi
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

10.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.

Authors:  Ashani T Weeraratna; Yuan Jiang; Galen Hostetter; Kevin Rosenblatt; Paul Duray; Michael Bittner; Jeffrey M Trent
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  29 in total

Review 1.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Authors:  Sean S Q Ma; Claire E Henry; Estelle Llamosas; Rupert Higgins; Benjamin Daniels; Luke B Hesson; Nicholas J Hawkins; Robyn L Ward; Caroline E Ford
Journal:  Virchows Arch       Date:  2016-09-08       Impact factor: 4.064

Review 3.  Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis.

Authors:  Ming Geng; Xuan Xin; Li-Quan Bi; Lu-Ting Zhou; Xiao-Hong Liu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer.

Authors:  Bo Sun; Xiufeng Ye; Li Lin; Mei Shen; Taotao Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  WNT5A inhibits hepatocyte proliferation and concludes β-catenin signaling in liver regeneration.

Authors:  Jing Yang; Antonella Cusimano; Jappmann K Monga; Morgan E Preziosi; Filippo Pullara; Guillermo Calero; Richard Lang; Terry P Yamaguchi; Kari N Nejak-Bowen; Satdarshan P Monga
Journal:  Am J Pathol       Date:  2015-06-19       Impact factor: 4.307

6.  Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.

Authors:  Jianjun Huang; Ying Shi; Hui Li; Dunyong Tan; Meisongzhu Yang; Xiang Wu
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

7.  ROR2 inhibits the proliferation of gastric carcinoma cells via activation of non-canonical Wnt signaling.

Authors:  Likun Yan; Qingguo Du; Jianfeng Yao; Ruiting Liu
Journal:  Exp Ther Med       Date:  2016-11-08       Impact factor: 2.447

8.  Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.

Authors:  Song-Zhu Yang; Jian-Tao Wang; Wei-Wei Yu; Qing Liu; Yan-Fang Wu; Shu-Guang Chen
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

9.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

10.  Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma.

Authors:  Peifeng Li; Yongcheng Cao; Yamin Li; Luting Zhou; Xiaohong Liu; Ming Geng
Journal:  Int J Clin Exp Pathol       Date:  2014-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.